Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Efficacy, and Tolerability of Tezacaftor/Ivacaftor (TEZ/IVA) in an Orkambi-experienced Population Who Are Homozygous for the F508del CFTR Mutation
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 25 Jul 2018
At a glance
- Drugs Ivacaftor/lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Registrational
- Sponsors Vertex Pharmaceuticals
- 18 Jul 2018 Planned End Date changed from 30 Jun 2018 to 1 Aug 2018.
- 18 Jul 2018 Planned primary completion date changed from 30 Jun 2018 to 1 Aug 2018.
- 18 Jul 2018 Status changed from recruiting to active, no longer recruiting.